e l f Beauty Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? e l f Beauty Inc trades at $105.97 (market cap $6.20B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.32 (market cap $2.27B). The key difference: e l f Beauty Inc is far larger — about 2.7× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals.
| ELF | SLS | |
|---|---|---|
Market Cap | $6.20B | $2.27B |
Volume | 1,301,240 | 4,179,659 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $15.46 |
52-Week Low | $49.57 | $1.39 |
Typical Hold Time | 25 Days | — |
Enterprise Value | $6.78B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported strong revenue growth, with 2025 revenue at $1.31B and net income of $112.09M, though 2026 projections show margin compression. Recent expansion includes the rhode brand launch in Europe via Sephora and marketing initiatives like the 'Mirror Mix' album.
The outlook is mixed: robust growth and analyst support (48% buy ratings) contrast with high valuation (P/E 107.17) and competitive pressures. Key risks include execution of international expansion and sustained profitability amid increased spending. The stock's current price sits above the consensus target of $95.91, suggesting limited near-term upside.
No Aura AI signal available yet.
Trailing returns across standard periods
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →